Lupin Q1 Review - Ex-Milestone Income, Disappointing Quarter, U.S. To Kick From FY23/24E: Dolat Capital
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Lupin Ltd. reported poor Q1 adjusted for the one-time milestone income of $50 million from Boehringer Ingelheim for a cancer drug.
Adjusted sales grew 11% YoY aided by domestic formulations, adjusted Ebitda margin at 14% versus our expectation of 19% margins for base business.
Factors such as pricing pressure in base portfolio including famotidine, phasing out of albuterol from spot buys to long term contracts and supply chain issues impacted U.S. sales at $172 million.
Bucking the trend of past six quarters of margin improvement, Q1 saw a sharp dip due to subdued U.S.
Lupin's management lowered Ebitda margin guidance from 18-20% to 16-17% for FY22E with recovery expected from Q3.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.